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Arginine Intake and Risk of Coronary Heart Disease
Mortality in Elderly Men
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Abstract—From experimental studies, the hypothesis is derived that the amino acid arginine, the precursor of NO, could
restore the impaired endothelial function and increased platelet activation observed in atherosclerosis. We investigated
whether dietary intake of arginine is associated with reduced coronary heart disease risk in elderly persons. The study
population consisted of 806 men aged 64 to 84 years at baseline who participated in the Zutphen Elderly Study, a
population-based cohort followed up for 10 years. Information about habitual food consumption was collected by use
of the cross-check dietary history method. Ninety (11.2%) of the 806 men died from coronary heart disease. Mean6SD
baseline arginine intake was 4.3561.07 g/d. Meat was the main source of arginine intake (37.1%), followed by bread
(13.1%) and milk and milk products (12.1%). Arginine intake was not associated with coronary heart disease mortality.
After adjustment for age, the relative risk (RR) for the medium tertile of arginine intake was 0.72 (95% CI 0.44 to 1.18),
and the RR for the highest tertile was 0.71 (95% CI 0.43 to 1.19, P for trend50.19) compared with the lowest tertile
of arginine intake. After additional adjustment for history of coronary heart disease and diabetes mellitus, energy intake,
body mass index, smoking habit, physical activity, and other relevant dietary and biological risk factors, the RR was 1.86
(95% CI 1.06 to 3.27) for the medium intake and 1.56 (95% CI 0.83 to 2.93) for the highest intake (P for trend50.17).
These results do not support the hypothesis that dietary arginine intake lowers the risk of coronary heart
disease mortality. (Arterioscler Thromb Vasc Biol. 2000;20:2134-2139.)
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The discovery of NO as a signaling molecule in thecardiovascular system was rewarded with the 1998
Nobel Prize in Medicine. The semiessential amino acid
L-arginine is the precursor of NO. It has been demonstrated
that administration of L-arginine can improve endothelium-
dependent vascular relaxation through the release of NO.1
Chronic dietary supplementation of L-arginine in hypercho-
lesterolemic animals has been associated with reduced ath-
erosclerosis and antiatherogenic effects, such as reduction in
surface area and intimal thickness of atheromatous lesions,
decrease of platelet aggregation, and attenuation of cell
proliferation and of vascular monocyte accumulation.2–8
In humans, endothelial dysfunction could be restored after
dietary supplementation9–12 and intravenous administration
of L-arginine13–15 in patients with hypercholesterolemia,9,13,14
heart failure,12 and nonobstructive or advanced coronary
artery disease.10,11,15 Reduction in platelet aggregation by
L-arginine has also been observed.16–18
Consequently, arginine was recently presented as a possi-
ble new pharmacological therapy for the atherogenic process
leading to coronary heart disease.19 Antiatherogenic effects of
arginine are especially demonstrated in human subjects with
more or less advanced atherosclerosis. Coronary atheroscle-
rosis is increasingly present in the elderly. Possibly, arginine
is associated with reduced coronary heart disease risk in
elderly persons. Therefore, we investigated the hypothesis
that dietary arginine intake is inversely associated with
coronary heart disease mortality among participants in the
Zutphen Elderly Study.
Methods
Study Population
The study population consisted of men who participated in the Zutphen
Elderly Study, an extension of the Zutphen Study, the Dutch contribu-
tion to the Seven Countries Study.20 In 1960, the Zutphen Study started
with a cohort of 878 men from Zutphen (the Netherlands) born between
1900 and 1919. In 1985, 367 of the 555 participants who were still alive
were reexamined. In addition, 711 other men from the town of Zutphen
in the same age category were asked to participate. A total of 939 men
(response rate 74%) were examined in 1985, and complete information
on diet and risk factors was available for 806 men. In 1990, 781 of these
939 men were still alive, and 560 took part in a follow-up examination.
Dietary intake in 1990, together with complete information on diet and
risk factors at baseline (1985) was available for 508 men.
Data Collection
Dietary and medical examinations were completed between March
and June 1985 and after 5 years of follow-up, between March and
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June 1990. Information about the habitual food consumption was
collected by use of the cross-check dietary history method, adapted
to the Dutch situation.21 Participants, together with the person who
prepared the meals, were interviewed about their usual food con-
sumption pattern during weekdays and weekends for the 2 to 4 weeks
preceding the interview. Quantities of food bought per week were
used to calculate and verify the food consumption of a participant on
an average weekday.
Nutrient intake data, including ethanol, were based on the Dutch
food table.22 Because of lack of information on the amino acid
composition of Dutch foods, arginine contents of chemical analysis
were used, preferably from the United Kingdom23 and subsequently
from the United States.24 The arginine contents were converted by
use of the protein contents from the Dutch food table.22
During medical examinations, nonfasting venous blood samples
were taken. Serum total cholesterol and HDL cholesterol were
determined enzymatically.25,26 In 1995, serum total homocysteine
was measured in serum stored at 220°C, as described previously.27
Weight and height were measured while participants were wearing
underwear only, and body mass index was calculated (kilograms per
meter squared). At the end of the physical examinations, blood
pressure was measured twice with participants in the supine position.
Information on smoking status (nonsmoker, exsmoker, or current
smoker), medication use, and history of hypertension and diabetes
mellitus was obtained by a standardized questionnaire. Patients with
insulin-dependent and non–insulin-dependent diabetes mellitus were
considered in the present study. Minutes of physical activity (mainly
walking, cycling, hobbies, sports, gardening, and work) per week
were calculated by use of a self-administered questionnaire origi-
nally designed for retired men.28 Information regarding a history of
coronary heart disease was obtained by using the Dutch translation of
the Rose questionnaire.29
Follow-Up
Information involving the vital status of all participants was obtained
from the municipal registries until January 1995. Three participants
were lost to follow-up. Information about the cause of death was
obtained from the Dutch Central Bureau of Statistics for deaths
occurring between baseline assessment and June 1990, after verifi-
cation with hospital discharge data and information from the de-
ceased’s general practitioners, and from the hospital discharge data
and/or participants’ general practitioners for deaths occurring there-
after, and if such information was not available, from the Dutch
Central Bureau of Statistics. Causes of death were coded according
to the ninth revision of the International Classification of Diseases
(ICD). Coronary heart disease refers to ICD codes 410 to 414.
Because the underlying cause of death in the elderly is often difficult
to determine, the primary (n584) and the secondary (n56) causes of
death were both considered in the analysis.
Statistical Methods
Differences in baseline characteristics of the participants between
tertiles of arginine intake were evaluated by ANOVA for normally
distributed variables, by Kruskal-Wallis test for skewed variables,
and by x2 test for categorical variables. Pearson correlation coeffi-
cients (rp) were calculated between the intake of arginine and other
dietary factors.
Energy-adjusted nutrient intake (ie, arginine) was computed as
residuals from the regression model, with energy intake as the
independent variable and nutrient intake as the dependent variable.30
Before computing the residuals of nutrient intake, the logarithmic
transformation of each nutrient variable, including arginine, was
calculated to improve the normality. Cox proportional hazards
(survival) analysis was used to calculate crude and adjusted relative
risks (RRs), 95% CIs, and probability values for linear trend. The
lowest tertile of arginine intake was taken as a reference group.
Several multivariate analyses were performed to take into account
potential confounding by major risk factors such as age, history of
coronary heart disease, smoking status, body mass index, and other
factors associated with arginine intake and potentially associated
with coronary heart disease mortality. To evaluate confounding, a
value of P,0.2 was considered. Energy-adjusted analysis included
the energy-adjusted tertiles of arginine intake plus a term for energy
intake. Interactions between arginine intake and relevant factors,
such as age, history of coronary heart disease, and smoking status,
were explored to determine whether the association between arginine
intake and coronary heart disease mortality differed among sub-
groups of the population. Proportional hazards analyses, including
arginine intake and all the covariables as time-dependent covariates,
were also performed. The baseline measurement (1985) for the first
5 years of follow-up and the measurement for the second 5 years of
follow-up (1990) were used. When the measurement for 1990 was
not available, only the baseline measurement was used for the total
follow-up period.
Results
Baseline
Mean6SD baseline arginine intake of the 806 participants
was 4.3561.07 g/d. Meat provided the largest contribution to
the total arginine intake (37.1%), followed by bread (13.1%)
and milk and milk products (12.1%). A relatively large
amount of arginine was also provided by peanuts (2.5%); this
was due to the high percentage of arginine in the protein of
peanuts (13.0%).
We examined the distribution of risk factors within cate-
gories of arginine intake. Arginine intake was inversely
associated with age, history of coronary heart disease, and
serum homocysteine levels and positively associated with
physical activity, alcohol use, and history of diabetes mellitus
(Table 1). However, the distributions of other risk factors did
not differ appreciably across the arginine categories. Con-
cerning dietary factors, arginine intake was positively asso-
ciated with the intake of (saturated and unsaturated) fat,
carbohydrates, protein, fiber, cholesterol, and total energy
(Table 2).
Daily intake of arginine was strongly correlated with the
intake of energy (rp50.65, P50.001). After adjustment for
energy, the associations between arginine intake and dietary
factors were weakened (Table 3). Energy-adjusted arginine
intake remained significantly positively associated with pro-
tein, dietary cholesterol, and fiber. In addition, energy-
adjusted arginine intake was positively associated with his-
tory of diabetes mellitus and body mass index and inversely
associated with age and serum homocysteine levels (data not
shown).
Follow-Up
During 10 years of follow-up, 374 participants died, of which
90 (11.2%) died from coronary heart disease. In the crude
analysis, arginine intake was inversely associated with the
risk of coronary heart disease, with an RR of 0.63 (95% CI
0.38 to 1.04) for the highest intake (P for trend50.07, Table
4). In different multivariate models, with potential confound-
ing by factors associated with arginine intake and potentially
associated with coronary heart disease mortality taken into
account, no inverse association between arginine intake and
coronary heart disease mortality was observed. Especially
because of the adjustment for energy intake, the RRs adjusted
for age, history of coronary heart disease, history of diabetes
mellitus, and energy intake were higher, 1.55 (95% CI 0.93 to
2.58) for the medium tertile and 1.19 (95% CI 0.68 to 2.07)
for the highest tertile of arginine intake. After adjustment for
body mass index, cigarette smoking, physical activity, alco-
hol consumption, and energy-adjusted intake of saturated
fatty acids, polyunsaturated fatty acids, cholesterol, and fiber,
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the RRs for the medium and high tertiles compared with the
lowest were 1.68 (95% CI 0.97 to 2.90) and 1.48 (95% CI
0.80 to 2.72), respectively. Tests for linear trend were not
statistically significant. The inclusion of serum total and HDL
cholesterol, blood pressure, and serum homocysteine as
potential confounders in the analysis increased the RRs
further (Table 4).
It may be questioned whether energy intake is a con-
founder in this population, because the association between
energy intake and coronary heart disease mortality was not
statistically significant in the adjusted analysis. Therefore, we
repeated the multivariate analysis (the full model, with
systolic blood pressure, cholesterol, and homocysteine) with-
out adjustment for energy intake. The RR was 0.88 (95% CI
TABLE 1. The Zutphen Elderly Study: Baseline (1985) Characteristics According to Tertiles of
Arginine Intake in 806 Men
Characteristic
Tertiles of Arginine Intake, g/d
P *
0–3.85 (Low)
(n5268)
3.86–4.65 (Medium)
(n5269)
.4.65 (High)
(n5269)
Age, y 72.365.4 71.765.3 70.064.8 0.0001
Body mass index, kg/m2 25.663.2 25.462.6 25.563.5 0.57
Smoking, %
Current smoker 29.9 29.0 31.2 0.85
Past smoker 51.9 52.8 49.8 0.78
Alcohol users, % 66.4 77.3 75.5 0.01
Physical activity, min/wk 4906484 6426562 6606559 0.0001
Systolic blood pressure, mm Hg 151622 152621 149620 0.25
Serum total cholesterol, mmol/L 6.1261.18 6.0161.08 6.2161.07 0.12
Serum HDL cholesterol, mmol/L 1.1160.33 1.1360.29 1.1360.26 0.16
Serum homocysteine, mmol/L 17.8610.5 15.266.8 13.966.0 0.0001
Medication use, %
Hypertension 11.9 14.5 9.3 0.18
Cholesterol lowering 2.6 1.1 0.8 0.17
History of coronary heart disease, % 23.9 16.4 16.0 0.03
History of diabetes mellitus, % 3.0 6.7 7.8 0.02
History of hypertension, % 22.8 21.2 17.1 0.24
Values are mean6SD.
*ANOVA for normal distributed variables, Kruskal-Wallis test for skewed variables, and x2 test for dichotomous
variables.
TABLE 2. The Zutphen Elderly Study: Baseline (1985) Mean Daily Nutrient Intake
According to Tertiles of Arginine Intake in 806 Men
Nutrient
Tertiles of Arginine Intake, g/d
P *
0–3.85 (Low)
(n5268)
3.86–4.65 (Medium)
(n5269)
.4.65 (High)
(n5269)
Arginine, g 3.3160.42 4.2260.23 5.5060.90 z z z
Energy, MJ 8.061.7 9.461.6 11.062.0 0.0001
Total fat, g 83.2624.3 101.6627.8 121.3633.6 0.0001
Saturated fatty acids, g 36.3611.6 43.7612.7 51.1615.2 0.0001
Monounsaturated fatty acids, g 31.1610.5 37.9612.2 46.0614.8 0.0001
Polyunsaturated fatty acids, g 12.666.2 16.267.7 19.568.8 0.0001
Carbohydrates, g 206660 228656 265665 0.0001
Total protein, g 62.968.7 78.866.6 98.5614.5 0.0001
Vegetable protein, g 20.265.1 23.965.4 29.668.2 0.0001
Animal protein, g 42.968.4 55.168.5 69.1614.4 0.0001
Alcohol, g 12.1616.1 14.7618.6 12.8616.2 0.07
Fiber, g 21.265.6 25.166.4 29.967.9 0.0001
Cholesterol, mg 275695 3406102 3996123 0.0001
Values are mean6SD.
*ANOVA for normal distributed variables, Kruskal-Wallis test for skewed variables, and x2 test for
dichotomous variables.
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0.49 to 1.56) for the medium intake and 0.99 (95% CI 0.50 to
1.98) for the highest intake (P for trend50.98).
We further examined whether the association between
arginine intake and coronary heart disease mortality was
modified by other risk factors, with use of an interaction term
in the multivariate analysis. Only for age was a significant
interaction observed. The association was significant and
more strongly positive in men below the median age of 71
years and inverse (but not significant) in men aged .71
years.
Finally, to reduce the likelihood that our results were
biased by changes in dietary intake and lifestyle, analyses
were also performed with the use of time-dependent covari-
ates. This resulted in significantly increased risks; in the full
multivariate model, the RR was 2.19 (95% CI 1.22 to 3.95)
for medium intake and 2.44 (95% CI 1.30 to 4.59) for the
highest intake (P for trend50.01).
Discussion
This is the first observational study investigating the associ-
ation between dietary arginine intake and coronary heart
disease mortality. We observed no beneficial effect of dietary
arginine intake on the risk of coronary heart disease in elderly
men.
Our results regarding arginine intake and coronary heart
disease mortality are not consistent with the antiatherogenic
effects of arginine experimentally demonstrated in human
subjects with more or less advanced atherosclerosis.9–18 In
healthy subjects, some experimental studies observed no
effect on endothelial function after infusion or supplementa-
TABLE 3. The Zutphen Elderly Study: Baseline (1985) Mean Daily Nutrient Intake
According to Tertiles of Energy-Adjusted Arginine Intake in 806 Men
Nutrient
Tertiles of Energy-Adjusted Arginine Intake, g/d
P *
0–3.91 (Low)
(n5268)
3.92–4.53 (Medium)
(n5269)
.4.53 (High)
(n5269)
Energy, MJ 9.562.3 9.562.1 9.462.1 0.67
Total fat, g 103.4634.5 102.2631.6 100.6632.2 0.63
Saturated fatty acids, g 44.8615.8 44.2614.1 42.1613.6 0.07
Monounsaturated fatty acids, g 38.4614.8 38.5612.9 38.1614.3 0.94
Polyunsaturated fatty acids, g 15.868.3 15.667.4 17.068.6 0.11
Carbohydrates, g 243667 236665 220661 0.0001
Total protein, g 68.568.7 79.5613.1 92.2617.4 0.0001
Vegetable protein, g 23.066.4 24.566.6 26.368.8 0.0001
Animal protein, g 45.7612.1 55.3610.7 66.2614.9 0.0001
Alcohol, g 14.8618.2 12.5617.8 12.3614.9 0.47
Fiber, g 23.366.9 25.666.4 27.368.3 0.0001
Cholesterol, mg 3166122 3386107 3606122 0.0001
Values are mean6SD.
*ANOVA for normal distributed variables, Kruskal-Wallis test for skewed variables, and x2 test for
dichotomous variables.
TABLE 4. RRs and 95% CIs for Mortality From Coronary Heart Disease in 806
Men During 10-Year Follow-Up According to Tertiles of Arginine Intake
Coronary Heart Disease Mortality
Tertiles of Arginine Intake*
P for
Trend
Low
(n5268)
Medium
(n5269)
High
(n5269)
No. of deaths 36 28 26
Mortality rate, per 1000 person-years 18.8 13.6 12.0
RRs
Crude 1.0 0.72 0.63 0.07
95% CI 0.44–1.19 0.38–1.04
Age-adjusted 1.0 0.72 0.71 0.19
95% CI 0.44–1.18 0.43–1.19
Multivariate† 1.0 1.87 1.58 0.16
95% CI 1.06–3.29 0.84–2.96
*Cutoff points were 3.85 and 4.66 g/d for the tertiles unadjusted for energy intake and 3.91 and
4.53 g/d for tertiles adjusted for energy intake (residual from regression analysis with energy intake).
†Factors include age, history of coronary heart disease, history of diabetes mellitus, energy intake,
body mass index, smoking, alcohol, physical activity, intake of saturated fatty acids, polyunsaturated
fatty acids, cholesterol, fiber (all as residuals from the regression model with energy intake), systolic
blood pressure, total and HDL cholesterol, and homocysteine.
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tion of arginine.31,32 Plasma arginine levels in these subjects
were also unaffected after supplementation.32 This finding
suggests that at least under normal conditions, sufficient
endogenous arginine can be synthesized to maintain the rate
of NO synthesis.33 However, some findings in healthy young
subjects showed that infusion of arginine could increase
vasodilatation and blood viscosity and reduce platelet aggre-
gation.34 Studies using a tracer for arginine also have shown
that dietary arginine can affect the endogenous arginine
metabolism and plasma arginine levels in humans.33,35 These
findings and those from experiments in humans with a high
risk profile for coronary heart disease suggest a relative lack
of endogenous arginine for the synthesis of NO, which could
be restored by arginine administration. Uncertainty remains
regarding the exact conditions in which insufficient endoge-
nous arginine is present.
An important limitation of the present study was that it
included only men aged 64 to 84 years at baseline. The
beneficial effects of arginine on vasodilatation might be
higher in younger populations because stiff arteries are not as
prevalent in the young. However, in the elderly, atheroscle-
rosis is increasingly present, just as in the subjects of
experiments in which the antiatherogenic effects of oral
L-arginine supplementation were demonstrated. Subgroup
analysis indicated that in the oldest men, arginine was
inversely associated with coronary heart disease mortality,
albeit nonsignificantly. On the basis of these data, however,
generalizability with respect to other age groups and women
is uncertain.
In experiments in which the antiatherogenic effects of oral
L-arginine supplementation were demonstrated, subjects were
supplemented with 3 to 21 g L-arginine per day during a
short10,17 or long9,11,12 period. The dose used in those exper-
iments was generally much higher than the average arginine
intake in the present study. Therefore, it cannot be excluded
that the effects of arginine on atherosclerosis are especially
present when large amounts of arginine are supplemented and
that the range of dietary arginine intake in our cohort was not
wide enough to observe an association.
A true inverse association between arginine intake and
coronary heart disease mortality could also be missed if the
measurement of the arginine content of the diet is imprecise.
Habitual food composition was measured by use of the
cross-check dietary history method, which is acknowledged
as a valid method in an epidemiological setting.21 Random
misclassification of dietary exposure due to error in the
quantification of arginine in food tables cannot be excluded.
Plasma arginine levels were not measured; however, these
might reflect short-term rather than long-term dietary intake
because of endogenous synthesis and conversion of argi-
nine.35 The estimate of daily average arginine intake of 4.4 g
of the Zutphen elderly population was comparable to the
estimated arginine intake of 4.2 g/d after 5 years of follow-up
(rp50.50, P50.001) and to the estimated average arginine
intake of the American diet of 5.4 g/d, which is based on the
arginine contents of foods available in 1970.36 In addition, by
use of the baseline measurement of arginine and the measure-
ment after 5 years of follow-up, arginine intake was even
more strongly positively associated with coronary heart
disease mortality compared with the measurement using
arginine intake at baseline only. Thus, it is unlikely that
misclassification of dietary exposure explains our findings.
Because higher arginine intake was associated with a
healthier lifestyle and diet, including a high energy intake, in
our study population, we used several multivariate models to
reduce residual confounding. A higher risk of coronary heart
disease mortality with arginine intake was observed with the
multivariate model. This apparent positive association is
probably due to chance, because there is no biological
explanation for this finding. Furthermore, the effect of
L-arginine on coronary heart disease mortality could be
confounded by other dietary factors that were not included in
our analysis. Because arginine is derived from different
foods, other dietary factors occurring in the same foods could
have affected the results for arginine. For instance, in addition
to arginine, nuts also contain other potentially protective
constituents.37 Furthermore, arginine intake is highly associ-
ated with the intake of other amino acids, such as methionine
(rp50.89, P50.001). However, our results are adjusted for
serum homocysteine, the intermediate in the potential asso-
ciation between methionine and coronary heart disease. Also,
other dietary factors influencing the arginine-NO pathway,
such as L-glutamine38,39 or vitamin C,40 could have interfered
with the role of arginine. Vitamin C could inhibit the
inactivation of NO by oxygen-derived free radicals. How-
ever, adjustment for intake of vegetables, fruit, or vitamin C
in the analysis did not appreciably change the results (data not
shown).
In conclusion, we observed no association between dietary
arginine intake and coronary heart disease mortality in a
cohort of elderly men. However, this result cannot be gener-
alized because of the elderly population studied and unmea-
sured dietary factors (potentially) associated with arginine.
Additional observational studies are needed, preferably in
other age groups in populations with a relatively high
arginine intake or on more specific parameters, such as
endothelial function. Furthermore, other lines of research,
including studies involving biomarkers for arginine intake,
should be carried out to confirm or reject the beneficial
impact of arginine on coronary heart disease suggested by
human and animal experiments.
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